

**REMARKS**

Claims 1-11, 14 and 16-20 are pending in this application. In this amendment, claims 12, 13 and 15 have been cancelled, claims 5, 7-11, 14 and 16 have been amended, and new claims 17-20 have been added. These claims have been amended to place them in form appropriate to US practice, such as, for example, removing multiple dependencies for the purpose of reducing fees.


Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted on accordance to 37 CFR 1.77. In addition, a portion of the specification on page 13, line 35 as referenced above has been amended to correct a minor typographical error in reference to a patent number.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



\_\_\_\_\_  
Robert J. Smith  
Attorney for Applicant  
Registration No. 40,820

Date: June 2, 2002

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-9616  
Facsimile: 919-483-7988